Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2031
- Registration Number
- NCT00624377
- Locations
- 🇨🇳
Boehringer Ingelheim Investigational Site 1, Taipiei, Taiwan
🇨🇳Boehringer Ingelheim Investigational Site 5, Taipiei, Taiwan
🇨🇳Boehringer Ingelheim Investigational Site, Taoyuan, Taiwan
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1899
- Registration Number
- NCT00623623
- Locations
- 🇮🇹
1123.28.39001A Boehringer Ingelheim Investigational Site, Monza, Italy
🇫🇷1123.28.3329A Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France
🇫🇷1123.28.3329C Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France
26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
- Conditions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 838
- Registration Number
- NCT00624052
- Locations
- 🇪🇸
1235.8.34005 Boehringer Ingelheim Investigational Site, Santa Coloma de Gramanet, Spain
🇪🇸1235.8.34004 Boehringer Ingelheim Investigational Site, Madrid, Spain
🇪🇸1235.8.34001 Boehringer Ingelheim Investigational Site, Jerez de la Frontera (Cádiz), Spain
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1560
- Registration Number
- NCT00622284
- Locations
- 🇺🇸
1218.20.10030 Boehringer Ingelheim Investigational Site, Topeka, Kansas, United States
🇺🇸1218.20.10035 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
🇺🇸1218.20.10003 Boehringer Ingelheim Investigational Site, Chula Vista, California, United States
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1878
- Registration Number
- NCT00621855
- Locations
- 🇨🇦
1160.67.11020 Boehringer Ingelheim Investigational Site, Sudbury, Ontario, Canada
🇨🇦1160.67.11018 Boehringer Ingelheim Investigational Site, London, Ontario, Canada
🇧🇪1160.67.32003 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 503
- Registration Number
- NCT00621140
- Locations
- 🇮🇹
1218.16.39004 Boehringer Ingelheim Investigational Site, Catanzaro, Italy
🇮🇹1218.16.39008 Boehringer Ingelheim Investigational Site, Genova, Italy
🇮🇹1218.16.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy
Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities
- Conditions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4918
- Registration Number
- NCT00621582
Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients
- Conditions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3008
- Registration Number
- NCT00620516
- Locations
- 🇰🇷
Boehringer Ingelheim Investigational Site 70, Gyeongnam, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 45, Jeonnam, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 69, Chungbuk, Korea, Republic of
Assessing the Impact of MOVALIS in Osteoarthritis and Rheumatoid Arthritis Patients on Health Related Quality of Life
- Conditions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3569
- Registration Number
- NCT00619177
- Locations
- 🇸🇰
Boehringer Ingelheim Investigational Site, Zilina, Slovakia
An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination
- Conditions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 259
- Registration Number
- NCT00618774
- Locations
- 🇯🇵
1235.16.001 Boehringer Ingelheim Investigational Site, Shinjyuku-ku,Tokyo, Japan
🇯🇵1235.16.006 Boehringer Ingelheim Investigational Site, Nishi-ku, Hiroshima, Hiroshima, Japan
🇯🇵1235.16.005 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan